RIPK1 was activated during SARS-CoV-2 infection, and inhibition of RIPK1 blocked SARS-CoV-2 infection and inflammatory cytokine production.17 We provided novel targets for COVID-19 therapies by determining how the SARS-CoV-2 infection activated these inflammatory signaling pathways. Here, RIPK1 is linked to COVID-19.